The Role of CXCL13 in Antibody Responses to HIV-1 Infection and Vaccination

Front Immunol. 2021 Feb 25:12:638872. doi: 10.3389/fimmu.2021.638872. eCollection 2021.

Abstract

CXCL13 signals through the G protein-coupled chemokine receptor CXCR5 to drive development of secondary lymphoid tissue as well as B cell and Tfh cell trafficking to germinal centers (GC), which leads to the differentiation of B cells to plasma cells and memory B cells. CXCL13 has been proposed as a general plasma biomarker for GC activities. In HIV-1 infected individuals, plasma CXCL13 levels have been associated with the rate of disease progression to AIDS. Moreover, CXCL13 production has been reported to be increased in HIV-1-infected lymph nodes, which may drive increased downregulation of CXCR5. In this review, we address the role of CXCL13 in HIV-1 infected individuals with regard to GC formation, generation of broadly neutralizing antibodies after infection and vaccination, and AIDS-related B cell lymphoma.

Keywords: CXCL13; CXCR5; HIV-1; broadly neutralizing antibodies; vaccine.

Publication types

  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • AIDS Vaccines / immunology*
  • Antibody Formation / immunology
  • Broadly Neutralizing Antibodies / immunology
  • Chemokine CXCL13 / immunology*
  • HIV Antibodies / immunology*
  • HIV Infections / immunology*
  • HIV-1 / immunology*
  • Humans

Substances

  • AIDS Vaccines
  • Broadly Neutralizing Antibodies
  • CXCL13 protein, human
  • Chemokine CXCL13
  • HIV Antibodies